Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I.

Activation of factor XI (FXI) by thrombin in vivo plays a role in coagulation by providing an important positive feedback mechanism for additional thrombin generation. FXI is activated in vitro by thrombin, or FXIIa in the presence of dextran sulfate. In this report, we investigated the effect of beta(2)-glycoprotein I (beta(2)GPI) on the activation of FXI. beta(2)GPI bound FXI in vitro and inhibited its activation to FXIa by thrombin and FXIIa. The affinity of the interaction between beta(2)GPI and FXI was equivalent to the interaction between FXI and high molecular weight kininogen. Inhibition of FXI activation occurred with lower concentrations of beta(2)GPI than found in human plasma. Proteolytic clipping of beta(2)GPI by plasmin abolished its inhibition of FXI activation. The results suggest a mechanism of regulation whereby physiological concentrations of beta(2)GPI may attenuate thrombin generation in vivo by inhibition of FXI activation. Plasmin cleavage of beta(2)GPI provides a negative feedback that counteracts its inhibition of FXI activation.

[1]  A. Gruber,et al.  Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. , 2003, Blood.

[2]  G. M. Iverson,et al.  Use of Single Point Mutations in Domain I of β2-Glycoprotein I to Determine Fine Antigenic Specificity of Antiphospholipid Autoantibodies1 , 2002, The Journal of Immunology.

[3]  Constantin A. Bona,et al.  The molecular pathology of autoimmune diseases , 2002 .

[4]  P. Walsh,et al.  Activated Platelets but Not Endothelial Cells Participate in the Initiation of the Consolidation Phase of Blood Coagulation* , 2002, The Journal of Biological Chemistry.

[5]  H. Billett,et al.  Elevated levels of Factor XI are associated with cardiovascular disease in women. , 2002, Thrombosis research.

[6]  E. Rosen,et al.  FXI Is Essential for Thrombus Formation Following FeCl3-Induced Injury of the Carotid Artery in the Mouse , 2002, Thrombosis and Haemostasis.

[7]  T. Renné,et al.  Characterization of the H-kininogen-binding Site on Factor XI , 2002, The Journal of Biological Chemistry.

[8]  G. M. Iverson,et al.  Heparin Inhibits the Binding of β2-glycoprotein I to Phospholipids and Promotes the Plasmin-mediated Inactivation of This Blood Protein , 2002, The Journal of Biological Chemistry.

[9]  P. Walsh.  Roles of Platelets and Factor XI in the Initiation of Blood Coagulation by Thrombin , 2001, Thrombosis and Haemostasis.

[10]  T. Koike,et al.  Detection of ‘antiphospholipid’ antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding β2‐glycoprotein I and prothrombin , 2001, Clinical and experimental immunology.

[11]  P. Walsh,et al.  Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential. , 2001, Blood.

[12]  H. Herzog,et al.  Impaired Thrombin Generation in β2-Glycoprotein I Null Mice* , 2001, The Journal of Biological Chemistry.

[13]  M. Suckow,et al.  The characterization of mice with a targeted combined deficiency of protein c and factor XI. , 2001, The American journal of pathology.

[14]  I. Nishii,et al.  Identification of the phospholipid-binding site of human beta(2)-glycoprotein I domain V by heteronuclear magnetic resonance. , 2000, Journal of molecular biology.

[15]  N. Ohkura,et al.  Highly increased plasma concentrations of the nicked form of beta(2) glycoprotein I in patients with leukemia and with lupus anticoagulant: measurement with a monoclonal antibody specific for a nicked form of domain V. , 2000, Journal of biochemistry.

[16]  P. Walsh,et al.  Thrombin-mediated Feedback Activation of Factor XI on the Activated Platelet Surface Is Preferred over Contact Activation by Factor XIIa or Factor XIa* , 2000, The Journal of Biological Chemistry.

[17]  F. Rosendaal,et al.  High levels of coagulation factor XI as a risk factor for venous thrombosis. , 2000, The New England journal of medicine.

[18]  N. Ohkura,et al.  Plasmin can reduce the function of human beta2 glycoprotein I by cleaving domain V into a nicked form. , 1998, Blood.

[19]  P. Walsh,et al.  Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor XI activation by thrombin. , 1998, Biochemistry.

[20]  A. Tincani,et al.  Apoptotic cell clearance in systemic lupus erythematosus: II. Role of β2-glycoprotein I , 1998 .

[21]  A Sali,et al.  Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. , 1996, Journal of immunology.

[22]  M. S. Rasmussen,et al.  Synchronized Inhibition of the Phospholipid Mediated Autoactivation of Factor XII in Plasma by β2-glycoprotein I and Anti-β2-glycoprotein I , 1995, Thrombosis and Haemostasis.

[23]  J. Hunt,et al.  The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. , 1994, Journal of immunology.

[24]  P. Hogg,et al.  Anticardiolipin Antibodies Block the Inhibition by β2-Glycoprotein I of the Factor Xa Generating Activity of Platelets , 1993, Thrombosis and Haemostasis.

[25]  S. Krilis,et al.  Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. L. La Porta,et al.  Activation of factor XI in plasma is dependent on factor XII. , 1993, Blood.

[27]  R. Colman,et al.  Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  I. Campbell,et al.  Activity, disulphate mapping and structural modelling of the fifth domain of human β2‐glycoprotein I , 1992 .

[29]  K Fujikawa,et al.  The coagulation cascade: initiation, maintenance, and regulation. , 1991, Biochemistry.

[30]  Robert B Sim,et al.  Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. , 1991, The Biochemical journal.

[31]  T. Barbui,et al.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor , 1990, The Lancet.

[32]  C. Chesterman,et al.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Day,et al.  Structure-function relationships of the complement components. , 1989, Immunology today.

[34]  J. Nimpf,et al.  Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. , 1987, Atherosclerosis.

[35]  P. Bomans,et al.  Prothrombinase activity of human platelets is inhibited by β2-glycoprotein-I , 1986 .

[36]  J. Griffin,et al.  Binding of coagulation factor XI to washed human platelets. , 1986, Biochemistry.

[37]  I. Schousboe.  beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. , 1985, Blood.

[38]  F. Putnam,et al.  Complete amino acid sequence of human plasma beta 2-glycoprotein I. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[39]  L. Knight,et al.  Blood coagulation factor XIa binds specifically to a site on activated human platelets distinct from that for factor XI. , 1984, The Journal of clinical investigation.

[40]  G. Kostner,et al.  Studies on the possible function of beta 2-glycoprotein-I: influence in the triglyceride metabolism in the rat. , 1982, Metabolism: clinical and experimental.

[41]  H. Brewer,et al.  Activation of human post heparin lipoprotein lipase by apolipoprotein H (beta 2-glycoprotein I). , 1980, Biochemical and biophysical research communications.

[42]  G. Kostner,et al.  The binding of beta 2-glycoprotein-I to human serum lipoproteins: distribution among density fractions. , 1979, FEBS letters.

[43]  K. Kurachi,et al.  Activation of human factor IX (Christmas factor). , 1978, The Journal of clinical investigation.

[44]  A. Kaplan,et al.  Association of factor XI and high molecular weight kininogen in human plasma. , 1977, The Journal of clinical investigation.

[45]  B. Osterud,et al.  Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. D. de Groot,et al.  β2-Glycoprotein I Is Proteolytically Cleaved In Vivo upon Activation of Fibrinolysis , 1999, Thrombosis and Haemostasis.

[47]  C. Hack,et al.  Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. , 1998, The Journal of clinical investigation.

[48]  A. Sali,et al.  Current insights into the "antiphospholipid" syndrome: clinical, immunological, and molecular aspects. , 1998, Advances in immunology.

[49]  J. Nishioka,et al.  β2-Glycoprotein I Modulates the Anticoagulant Activity of Activated Protein C on the Phospholipid Surface , 1996, Thrombosis and Haemostasis.

[50]  C. Chesterman,et al.  Immunology and clinical importance of antiphospholipid antibodies. , 1991, Advances in immunology.

[51]  R. Colman.  Hemostasis and thrombosis: Basic principles and clinical practice , 1987 .